Pharmacokinetics Study of FIA586 in Participants With Mild and Moderate Hepatic Impairment

A Phase I, Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics, Safety, and Tolerability of FIA586 in Participants With Mild and Moderate Hepatic Impairment Compared to Matched Healthy Participants

ClinicalTrials.gov Identifier: NCT04993157

Novartis Reference Number: CFIA586A02101

Last Update: Dec 23, 2021

See if you pre-qualify

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. 

Study Description

This is a Phase I study designed to characterize the pharmacokinetics (PK), safety, and tolerability of a single oral dose of FIA586 in participants with mild and moderate hepatic impairment (HI) compared to matched healthy participants.The information obtained in this study will help to determine whether dosage adjustment for FIA586 is necessary in patients with advanced liver fibrosis who have mild to moderate HI.

Condition 
Hepatic Impairment
Phase 
Phase 1
Overall status 
Recruiting
Start date 
Dec 10, 2021
Completion date 
May 20, 2022
Gender 
All
Age(s)
18 Years - 70 Years (Adult, Older Adult)

Interventions

Drug
FIA586
FIA586 capsule
Drug
FIA586
FIA586 capsule
Drug
FIA586
FIA586 capsule

Eligibility Criteria

Inclusion Criteria:

All Participants:

Male and non-childbearing potential female participants 18 to 70 years of age (inclusive) at Screening.
Must weigh at least 50.0 kg and must have a body mass index (BMI) within the range of 18.0 to - 38.0 kg/m2 at Screening.
Must be a non-smoker or agree to smoke no more than 5 cigarettes (or equivalent) per day, and maintain the same smoking status from Screening until the Study Completion (Day -28 to Day 6).

Healthy participants (Group 1)

Must be in good health as determined by past medical history, physical examination, vital signs, ECG, and laboratory tests at Screening.
Each participant must match in age (±10 years), gender, weight (±15%), and smoking status (smoker or non-smoker) to an individual participant in at least one HI group but not to more than 1 participant in the same HI group.

Participants with mild and moderate HI (Groups 2 and 3)

• Must satisfy the criteria for HI as evidenced by a Child-Pugh class of A or B at Screening:

Class A; Mild; Child-Pugh score 5-6
Class B; Moderate; Child-Pugh score 7-9

Exclusion Criteria:

All participants:

Use of other investigational drugs within the last 30 days or 5 half-lives prior to dosing of study treatment, whichever is longer.
Known history of, or current clinically significant arrhythmias. Have clinically significant ECG abnormality or history of long-QT syndrome.
Myocardial infarction < 5 years prior to Screening.
Recent (within the last 3 years of Screening) or recurrent history of autonomic dysfunction (e.g. recurrent episodes of fainting or palpitations).
History of immunodeficiency diseases or have a positive HIV test result at Screening.
History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in-situ cervical cancer), treated or untreated, within the past 3 years of Screening, regardless of whether there is evidence of local recurrence or metastases.

Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs (apart from cholecystectomy), or which may jeopardize the participants in case of participation in the study. The investigator should make this determination in consideration of the participant's medical history and/or clinical or laboratory evidence of any of the following:

Inflammatory bowel disease, peptic ulcers, gastrointestinal including rectal bleeding within 3 months prior to Screening.
Major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection.
Pancreatic injury or pancreatitis.

Healthy participants (Group 1):

Any single parameter of alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transferase (GGT), or alkaline phosphatase (ALP) exceeding 1.2 × upper limit of normal (ULN) or ≥ 1.5 × ULN total bilirubin (TBL) OR any elevation above ULN of more than one parameter of ALT, AST, GGT, ALP, or serum bilirubin at screening.
Known to have Gilbert's syndrome.
Hemoglobin levels below 12.0 g/dL for males and 11.0 g/dL for females at Screening or Baseline.
History or presence of impaired renal function as indicated by clinically significant abnormal creatinine or blood urea nitrogen (BUN) and/or urea values, or abnormal urinary constituents at Screening.
Total white blood cell (WBC) count which falls outside the range of 3.5 to 10.7 × 109/L, or platelets < 100 × 109/L at Screening or Baseline.
Evidence of urinary obstruction or difficulty in voiding at Screening.
Symptomatic genital or urinary tract infection in the 4 weeks prior to dosing of study treatment or the presence of active urinary tract infection at Screening.

Participants with mild and moderate HI (Groups 2 and 3):

Have abnormal laboratory values for any of the following parameters at Screening or Baseline:

Hemoglobin < 9 g/dL.
Platelet count < 30 × 109/L.
WBC count < 2.5 × 109/L.
Absolute neutrophil count < 1.5 × 109/L.
Lymphocytes < 0.8 × 109/L.
TBL > 8 mg/dL.
Serum amylase > 2 × ULN.
International normalized ratio (INR) > 2.3
Corrected serum calcium < 8.6 or > 10.2 mg/dL.
Hepatic impairment due to non-liver disease.
Presence of any non-controlled and clinically significant disease that could affect the study outcome or that would place the participant at undue risk.
Treatment with any vasodilator, autonomic alpha blocker or β2 agonist within 2 weeks prior to dosing of study treatment.
Primary biliary cholangitis or biliary obstruction.
Participants requiring paracentesis more than every 30 days for the management of ascites are excluded. Participants who are receiving diuretics to manage ascites may be enrolled and will be assigned the Child-Pugh score for the degree of ascites while on diuretic treatment. The diuretic dose must have been stable for 28 days prior to dosing of study treatment.
Have transjugular intrahepatic portosystemic shunt and/or have undergone portacaval shunting.
Have encephalopathy Grade 3 or worse within 28 days prior to dosing of study treatment.
Presence of moderate to severe impaired renal function as indicated by estimated glomerular filtration rate (eGFR) < 50 mL/min/1.73 m2 based on the modification of diet in renal disease calculation at Screening.

Other protocol-defined inclusion/exclusion criteria may apply.

Study Locations

United States
Orlando Clinical Research Center
Recruiting
Orlando, 32809 - Florida
Contact: IP
United States
Orlando Clinical Research Center
Recruiting
Orlando, 32809 - Florida
Contact: IP
United States
Orlando Clinical Research Center
Recruiting
Orlando, 32809 - Florida
Contact: IP
United States

Contacts

Name: 
Novartis Pharmaceuticals
Phone: 
Name: 
Novartis Pharmaceuticals
Phone: 
Name: 
Novartis Pharmaceuticals
Phone: 

Have a question?

Call 1-888-669-6682 or email [email protected]